Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Fundamentals of Liver Disease - Hepatitis B 2.0

    Contains 25 Component(s), Includes Credits Recorded On: 10/15/2020

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front-line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:

    HBV: Epidemiology and Screening
    Patient with Positive Hepatitis B Serologies
    Natural History of HBV and Identification of Treatment Candidates
    Management of the Chronic HBV Patient with Co-morbid and Other Conditions
    Antiviral Treatment of the Patient with Chronic HBV
    Prevention of HBV Infection
    Hepatitis B in the Pediatric Patient

    Release date: October 15, 2020
    Expiration date: October 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™   
    Continuing Education (CE): For a maximum of 3.50 Contact Hour 
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points


    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:

    -7 online interactive, narrated modules 20 to 30 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete all components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION 
    For questions on CME and MOC content or LiverLearning®, contact online_education@aasld.org 
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objectives:
    • Identify patients with liver disease
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for different liver diseases
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 3.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 3.50 MOC Points
    Continuing Education (CE): For a maximum of 3.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 3.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS 
    Physicians and other health care professionals for a maximum of 3.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by October 14, 2023

    CLAIMING CE CREDITS
    Nurses for a maximum of 3.50 contact hours for this enduring continuing education material must be completed by October 14, 2023

    CLAIMING ABIM MOC POINTS  
    Physicians seeking ABIM MOC credit must complete the enduring material by October 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through October 2023 for individuals who successfully complete MOC.

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-tests

                 o    Watch video presentations

                 o    Complete the post-tests and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    Marc G. Ghany

    Marc G. Ghany, MD, MHSc, FAASLD is an Investigator at the Liver Diseases Branch of the National Institute of Diabetes and Digestive and Kidney Diseases, and at Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda. He is member the Physician Consortium for Practice Improvement for Hepatitis C, which is jointly sponsored by the American Medical Association and AASLD and serves on the hepatitis C Guidance panel which is jointly sponsored by the AASLD and Infectious Diseases Society of America. His work has been honored with the Regal Award for Excellence in Gastrointestinal and Liver Disease and with several NIDDK service awards including the Director’s Award. He received his M.B. and B.Ch. from the Royal College of Surgeon’s, Dublin, and Master of Health Sciences in Clinical Research, Duke University. He completed residency at the Hospital of Saint Raphael, New Haven, Connecticut, a fellowship in gastroenterology at Tulane University, New Orleans, and a clinical fellowship at the Liver Diseases Section, NIDDK. Dr. Ghany’s focus is on translational research to improve the care and treatment outcomes of patients with chronic viral hepatitis. 

     

    Tram T. Tran

    Tram T. Tran, MD, FAASLD is the Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Norah A. Terrault

    Norah A. Terrault, MD, MPH, FAASLD is a Professor of Medicine and Chief of Gastroenterology and Liver Diseases at the Keck School of Medicine at University of Southern California. She received her MD from the University of Alberta and completed fellowships in Internal Medicine and Gastroenterology at the University of Toronto and a master’s in public health at the University of California at Berkeley. 

    Dr. Terrault has focused her clinical and research activities on viral hepatitis and non-alcoholic fatty liver disease, especially in special populations including those with cirrhosis and those with transplants. In addition to multiple clinical trials related to preventing and treating chronic hepatitis viral hepatitis and fatty liver, Dr. Terrault has been PI on multiple NIH-funded studies, including the current NIH-supported HBV clinical research network (HBRN) and nonalcoholic steatohepatitis clinical research network (NASH CRN). She has authored 330 peer-reviewed manuscripts, editorials, invited reviews as well as US national guidelines for treatment of chronic hepatitis B and C. She is past associate editor for Hepatology and deputy editor for Liver Transplantation and co-edited Zakim and Boyer’s textbook in hepatology. 

    Dr. Terrault is the founder of ECHO-Plus, a multifaceted program to train and support primary care physicians in California to care for patients with hepatitis. She has a long history of mentoring fellows and junior faculty in clinical research and is passionate about creating research support and opportunities for the next generation of GI/Hepatology investigators. Dr. Terrault was recently elected as Councilor to the AASLD governing board and will serve as president in 2023.

    Marion G. Peters

    Marion G. Peters, MBBS, MD, FAASLD is an Emeritus Professor of Medicine at the University of California at San Francisco and Adjunct Professor of Medicine at Northwestern University, Chicago. She is a hepatologist with a particular interest in viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection.  She led the NIH AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group (TSG) for 4 years where she championed young investigators to be chairs of new trials in Hep TSG. She is the Protocol Facilitator for ACTG Hepatitis TSG HBV-related studies, focusing on the development of US and international studies for new drugs for patients with HBV, with and without HIV. She is currently a team member or co-chair of 4 ACTG hepatitis trials. She is also a member of the HEP TSG steering committee.

    Dr. Peters serves on the scientific Advisory Board of International Antiviral Society USA, HEP DART and is a senior advisor to International Coalition to Eliminate HBV. She is an editor for the Journal of Antimicrobial Chemotherapy. She has trained fellows, house staff and medical students in clinical and translational research, many of whom have gone on to faculty positions focusing on liver disease. She has mentored faculty and fellows in her institution, nationally and internationally. She is particularly focused on mentoring women in medicine.  She has numerous publications on viral hepatitis with and without HIV coinfection in peer-reviewed journals with multiple collaborators.




    Anna S. Lok

    Anna S. Lok, MD, FAASLD graduated from the University of Hong Kong Medical School. She completed her hepatology training in London under Dame Sheila Sherlock.  She joined the University of Michigan in 1995 as Director of the Hepatology Program. She became Associate Chair for Clinical Research in the Department of Internal Medicine in 2008 and Assistant Dean for Clinical Research in 2016. 

    Dr. Lok’s research focuses on natural history and treatment of hepatitis B and C. She has published more than 550 papers on viral hepatitis and liver diseases including the American Association for the Study of Liver Diseases (AASLD) guidelines on “Hepatitis B”. She also participated in the development of the first World Health Organization guidelines on hepatitis B and C. Dr. Lok has made important contributions to the understanding of factors influencing the progression of hepatitis B and C, and the development of new treatments of these diseases. 

    Dr. Lok received many awards throughout her career including the Distinguished Scientist Award from the Hepatitis B Foundation in 2008, the Distinguished Service Award from the AASLD in 2011, the William Beaumont Prize in Gastroenterology from the American Gastroenterological Association in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an Hon DSc from the University of Hong Kong in 2017, an International Recognition Award from the European Association for the Study of the Liver in 2018, and a Distinguished University Professorship from the University of Michigan in 2019. 

    Dr. Lok served as Associate Editor of HEPATOLOGY in 2002-6, co-Editor of Journal of Viral Hepatitis in 2007-9, Senior Associate Editor of GASTROENTEROLOGY in 2011-2012, and President of AASLD in 2017. 

    Brian McMahon

    Brian J. McMahon MD, FAASLD is Director of the Liver Disease and Hepatitis Program at the Alaska Native Medical Center (ANMC) in Anchorage, Alaska. Dr. McMahon has served as co-author of the AASLD Practice Guideline for Hepatitis B between 2009 and 2018 and is co-Author of the AASLD Hepatitis B Guidance 2019. He was also the co-chair of the WHO Hepatitis Guideline published in 2015. He directed a program that halted transmission of hepatitis B in the Alaska Native population in the 1980’s, the only US born population endemic for persons with chronic hepatitis B. He oversees the management and care of over 1,000 Alaska Native persons with chronic hepatitis B.

    Dr. McMahon has served on the editorial board of Hepatology. He was previously chair of the AASLD Practice Guidelines Committee, was on the AASLD Nominating Committee and was previously chair of the Hepatitis B SIG. He received the AASLD distinguished Mentor/Clinician Award for 2017 for contributions in the global elimination of hepatitis B. He has received multiple NIH and CDC research grants and directs a team of investigators in Alaska. He conducts research in Alaska Native People including hepatitis A and B vaccine long-term efficacy, hepatitis B and C outcome, autoimmune liver diseases and NAFLD. He also has been involved in two hepatitis B projects funded by the Global AIDS program and the CDC Foundation in Tanzania and Zanzibar Africa. He teaches medical students at the University of Alaska/University of Washington WWAMI program, precepts medical students, residents in hepatology clinic and mentors medical students’ research projects. He holds a position as a Research Associate at the Arctic Investigations Program of the CDC located on the ANMC campus in Anchorage. He is Clinical Professor of Medicine at the University of Washington, School of Medicine in Seattle and Auxiliary Professor of Health Sciences at the University of Alaska, Anchorage. He has published over 160 peer review original articles plus over 50 review articles, guidelines/guidance statements and editorials.

    Maureen M. Jonas

    Maureen M. Jonas, MD, FAASLD is the Director of the Center for Childhood Liver Disease in the Division of Gastroenterology, Hepatology and Nutrition at Boston Children’s Hospital, and Professor of Pediatrics at Harvard Medical School.  Her area of expertise is Pediatric Hepatology and Liver Transplantation, with a special emphasis on viral hepatitis in children. She is the author of a number studies of therapies for pediatric viral hepatitis.

    Dr. Jonas has served on several AASLD committees, including the Practice Guidelines Committee, Ethics Committee and Nominating Committee.  She chaired several symposia sponsored by AASLD and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition at AASLD annual meetings.  She has served as abstract reviewer for AASLD meetings, and ad hoc reviewer for Hepatology.  Jonas established the Pediatric Transplant Hepatology training Program at Boston Children’s Hospital and served as its director until 2016.  She was the Medical Director of the Liver Transplant Service at BCH from 1991 through 2014. As an active educator, she has mentored numerous pediatric gastroenterology and hepatology fellows, as well as junior faculty, over the last 30 years.  She currently serves on the Transplant Hepatology Examination Committee for the American Board of Pediatrics.  She has been the lead Principal Investigator for many multinational pediatric viral hepatitis trials and has lectured extensively on this topic around the country and around the world.

    DISCLOSURE OF CONFLICTS OF INTEREST 
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Marc G. Ghany, MD, MHSc, FAASLD
    Faculty
    Nothing to disclose

    Tram T. Tran, MD, FAASLD
    Faculty
    Employment: Gilead Sciences (Unrelated)

    Norah Terrault, MD, MPH, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences and Roche/Genetech

    Marion G. Peters, MD, FAASLD
    Faculty
    Faculty/Advisory Committee or Review Panels: Antios, Atea and Aligos
    Employment (Spouse): Genentech Research and Development (subsidiary of Roche)

    Anna S.F. Lok, MD, FAASLD
    Faculty
    Advisory Board: CLEAR-B, Gilead Sciences, GlaxoSmithKline, Huahui, Roche, Spring Bank, and TARGET PharmaSolutions
    Grant/Research Support: Assembly Biosciences, Bristol Myers Squibb, Gilead Sciences, and TARGET PharmaSolutions (to University of Michigan)

    Brian J. McMahon, MD, FAASLD
    Faculty
    Grant/Research Support: Gilead Sciences - Grant received by department at institution and not directly.

    Maureen M. Jonas, MD, FAASLD
    Faculty/Advisory Committee or Review Panels: Served as chair of DSMB for Gilead Sciences
    Grant/Research Support: AbbVie, Gilead Sciences, Roche and Merck. Echosens (equipment only)

    Lauren A. Beste, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Amanda J. Chaney, DNP, APRN, FNP-BC 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Royalities: Springer Publishing-Author 

    Leslie Hayes, MD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Nothing to disclose 

    Vicki Shah, PA 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board 

    Raj Vuppalanchi, MD, FAASLD 
    Fundamentals of Liver Disease Committee/Organizer/Reviewer 
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Dominique Clayton 
    AASLD Staff
    Nothing to disclose

    Denise Seise 
    AASLD Staff 
    Nothing to disclose

    Sheryl Morgan 
    Amedco LLC Staff 
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.


  • 2020 Webinar: Treatment Strategies for Autoimmune Hepatitis Beyond First-line Therapy

    Contains 2 Component(s) Recorded On: 10/14/2020

    Webinar hosted by the Cholestatic and Autoimmune Liver Diseases Special Interest Group on October 14, 2020.

    Treatment failure. Incomplete response. Treatment intolerance. Management of autoimmune hepatitis can be extremely challenging when first-line therapy is inadequate. Join us for a discussion of alternative treatment options for autoimmune hepatitis and a review of their efficacy. Learn about updates to the treatment paradigm from the new 2019 guidelines!

  • 2020 Webinar: Novel Models for HCV Care Delivery

    Contains 2 Component(s) Recorded On: 10/06/2020

    Webinar hosted by the Hepatitis C Special Interest Group on October 6, 2020.

    In order to achieve the World Health Organization's goal of treating at least 80% of identified HCV-infected patients, novel models of HCV care delivery should be implemented. This webinar will address telemedicine and digital telemedicine with respect to HCV care and will attempt to demonstrate improved models of linkage to care in both urban and exurban settings.

    John D. Scott

    John Scott, MD, MSc is a Professor of Medicine (Division of Allergy and Infectious Diseases) and Medical Director of Digital Health at the University of Washington. He graduated from Stanford University with a degree in Human Biology, attended Georgetown University School of Medicine cum laude, completed a residency in Internal Medicine at Stanford University Hospitals, and then obtained sub-specialty training in Infectious Diseases at the University of Washington.

    In 2009, he launched Project ECHO (Extension for Community Health Outcomes) in Washington State, the first place to replicate the ECHO model outside of New Mexico. This innovative telehealth program helps clinicians serving in rural and underserved areas with the evaluation and treatment of common, complex, chronic diseases. In 2015, he won the Warren Reid Award for excellence in health care for the state of Washington, in recognition of his telehealth work. He chairs the Washington State Telehealth Collaborative and serves on the Telehealth committee for the Infectious Disease Society of America.

    Jennifer C. Price

    Jennifer Price, MD, PhD is an Associate Professor in the Department of Medicine and Division of Gastroenterology and Hepatology at the University of California, San Francisco (UCSF) and Director of the UCSF Viral Hepatitis Center. Her research examines the contributions of novel and traditional factors associated with liver disease and fibrosis progression in large observational HIV cohorts, with or without viral hepatitis. Dr. Price is a PI of the San Francisco Bay Area site of the Multicenter AIDS Cohort Study (MACS)/Women’s Interagency HIV Study (WIHS) Combined Cohort Study (MWCCS), which integrates two of the largest and longest running NIH-funded prospective cohorts of men and women with and at risk for HIV in the U.S. She also serves as co-Chair of the MWCCS Liver Working Group and Vice Chair of the AASLD HCV SIG. Dr. Price is a member of the End Hep C SF Coordinating Committee and leads the UCSF HCV Project Extension for Community Healthcare Outcomes (ECHO), a collaborative model of medical education and care management focused on building capacity for HCV care among primary care providers throughout Northern California. She is the founding director of the DeLIVER Care Van, a mobile unit aimed at improving access to HCV screening and high-quality liver-related health care among marginalized communities.

    Sally Hodder

    Sally Hodder, MD is a Professor Medicine, Associate Vice President for Clinical and Translational Research at West Virginia University and Director and Principal Investigator (PI) of the West Virginia Clinical and Translational Science Institute. A graduate of Case Western Reserve University School of Medicine, she has been on the front lines of the HIV epidemic since she was an intern at the University of California San Francisco in 1980. After completing infectious diseases fellowship training, she saw first-hand the emergence of AIDS in Africa while working on a Schistosomiasis haematobium project in Coast Province, Kenya. Subsequently, she has had extensive experience leading large scientific programs (both academia and pharma). From 2003-2005, she served as Vice President of Virology Medical Affairs, Bristol-Myers-Squibb. In 2005, Dr. Hodder was recruited to New Jersey Medical School in Newark, New Jersey to build an HIV program where HIV prevalence was nearly 3% among the African American community. She served as Medical Director for a large HIV clinic in Newark and was successful in obtaining funding for both HIV treatment and prevention trials. She served as Protocol Chair for the NIH-funded HIV Prevention Trials Network 064 trial, a study of HIV incidence and risk behaviors among 2,099 U.S. women. In 2014, West Virginia University recruited Dr. Hodder to direct and serve as Principal Investigator of the West Virginia Clinical and Translational Science Institute, funded by the NIH. During her tenure, the West Virginia Practice-Based Research Network was developed which now includes 107 primary care sites across West Virginia, the Extension for Community Healthcare Outcomes (ECHO) to enhance rural primary care providers’ knowledge was implemented, and opioid use disorder and resultant emergent epidemics (e.g., hepatitis B, C, and HIV) were made a programmatic focus. She again finds herself on the front lines as HIV outbreaks are emerging in West Virginia.

    Lisa Catalli (Moderator)

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.

  • 2020 Webinar: Current and Future Disease Burden of HBV: Global and Regional Perspectives

    Contains 3 Component(s) Recorded On: 09/18/2020

    Webinar hosted by the Hepatitis B Special Interest Group on September 18, 2020.

    In this on-demand webinar, representative speakers from Africa including North and Sub-Saharan Africa (Mark W. Sonderup, South Africa), East Asia (Jidong Jia, China), West and South Asia (Shiv K. Sarin, India), Europe including Western and Eastern Europe (George V. Papatheodoridis, Greece), North America (Carla Coffin, Canada) and South/Central America (Adrian Gadano) will each talk on HBV disease burden and primary challenges in their respective regions. They will present the current status and predictions for the next decade. The live question and answer session, the discussion will focus on the challenges and opportunities in each region.

    Participants will be able to:

    Have a global view from regional perspectives on the current situation and future prediction of HBV disease burden and to discuss the actions (most critical/effective/cost-effective) required to improve the predictions toward a more desirable goal in the region.

    Promote the global outreach of AASLD by addressing issues that interest local audience.

    Mark W. Sonderup

    Mark Sonderup, MBChB is an associate professor in the Department of Medicine and Division of Hepatology. In 1995, he graduated from the University of Cape Town. Following his internship training, his postgraduate training was at the University of Cape Town and Groote Schuur Hospital. He obtained a Fellowship of the College of Physicians in 2002. Between 2002 and 2004, he completed a 2-year fellowship in Hepatology at the UCT/Medical Research Council Liver Research Centre and Liver Clinic at Groote Schuur Hospital, Cape Town. He briefly worked in the UK before being appointed as a Senior Specialist in the Department of Medicine and Division of Hepatology at UCT and Groote Schuur Hospital in 2007. He was granted a FRCP (London) in 2018.

    Sonderup research interests include viral hepatitis and drug induced liver injuries. He assisted in co-authoring the national viral hepatitis guidelines and elimination strategy for South Africa. Currently he serves on the WHO Strategic Advisory Committee on Viral Hepatitis.

    Shiv K. Sarin

    Shiv K. Sarin, MD, FAASLD is the senior professor of hepatology and director of Institute of Liver and Biliary Sciences (ILBS), New Delhi. He was instrumental in setting up the Institute of Liver and Biliary Sciences, under the auspices of the Govt of Delhi. He is also the director, WHO Collaborative Centre on Chronic Liver diseases and Viral Hepatitis at ILBS. He serves as adjunct faculty, Molecular Medicine at JNU due to his deep interest and contributions to translational science. He was credited with several new treatment protocols for liver diseases, specifically variceal bleeding, liver regeneration, hepatitis B and acute-on-chronic liver failure. He has more than 620 publications to his credit, edited 13 books on liver diseases and contributed 87 chapters in various medical textbooks. He has helped develop 19 major guidelines: including six major Asian Pacific Treatment Guidelines in Liver diseases.

    Sarin’s leadership roles include serving as president of the Indian Society of Gastroenterology, Indian Association for the Study of the Liver, Asian Pacific Association of Liver (APASL) and chairman steering committee of the APASL. He was awarded the prestigious 2017 Henry L. Bockus Medal by World Gastroenterology Organization. He was bestowed with Padma Bhushan by the government of India. He was a recipient of Shanti Swarup Bhatnagar Award, The World Academy of Medical Sciences (TWAS) International Prize, EASL International Recognition Award, Om Prakash Bhasin Award, Dhanvantri Medical Award, Ranbaxy Medical Sciences Award and the ‘Best Teacher’ Award. He, along with other Board of Governors, developed the ‘Vision 2015’ document for Medical Education in India during his tenure as chairman of Medical Council of India.

    George V. Papatheodoridis

    George Papatheodoridis, MD, PhD, FAASLD is a professor in medicine and gastroenterology at Medical School of National and Kapodistrian University of Athens and Director of the Academic Gastroenterology Department and the Liver Transplantation Unit of “Laiko” General Hospital of Athens, Greece. He is also the president of the Hellenic Transplant Organization. In October 1986, he was trained in Medicine at the Medical School of Athens University and graduated with excellence (9.2/10). In February 1996, he completed his PhD thesis at the Medical School of Athens University. He was trained in Gastroenterology at Tzaneion Hospital of Piraeus, Greece and had a two-year research fellowship in Hepatology at the Royal Free Hospital of London, UK (01/1997-01/1999).

    Papatheodoridis has served in many international and national associations. He is a member of EASL and American Association for Study of Liver Diseases (AASLD fellow) and founding member and treasurer of Hepatitis B and C Public Policy Association. He is president of Hellenic Foundation of Gastroenterology and Nutrition. His main research interest has been focused on viral hepatitis. He has co-authored more than 315 papers published in PubMed journals having total IF>2000 and >1600/25000 citations (h-index 62/74) in Scopus/Google Scholar. He was an associate editor of Liver International and served as an editorial board member and reviewer of several international journals. He has given more than 160 lectures, chaired over 50 lectures/round tables and presented over 300 abstracts in international meetings.

    Carla S. Coffin

    Carla Coffin, MD is an associate professor of medicine (2016), Cumming School of Medicine, University of Calgary and Medical Director of the Calgary Liver Unit, Calgary Division of Gastroenterology and Hepatology, Alberta Health Services, Alberta, Canada. She received MSc degree using the woodchuck HBV model with Professor TI Michalak and MD from Memorial University of Newfoundland, NL. She completed Internal Medicine and Gastroenterology fellowship at the University of Calgary, AB followed by an American Association for the Study of Liver Disease (AASLD) Advanced Hepatology Fellowship with Professor NA Terrault at the University of California, San Francisco.

    Coffin was a recipient of a Canadian Institutes of Health Research (CIHR) New Investigator Award (2012-2017). Her research has been supported by CIHR, AASLD, the American Gastroenterology Association, Canadian Foundation for Innovation / Alberta Advanced Education Technology, Alberta Innovates and Industry partners. She was first author on the 2012 and 2018 Canadian Association for the Study of the Liver (CASL) Hepatitis B guidelines and is Chair of the CASL Education Committee (2019-2021). She served on the World Health Organization (WHO) Expert Advisory Panel on Drug Evaluation (2015) and extended as on call WHO advisor until 2021. She has an active translational research program in hepatitis B with 90 peer-reviewed publications, has participated in more than 20 hepatitis B clinical trials and was integral to establishing the Canadian Hepatitis B Research Network.

    Adrián C. Gadano

    Adrián Gadano, MD is an associate professor in Physiology, Gastroenterology and Hepatology at the Italian Hospital School of Medicine, Argentina. He oversees the Liver Unit and Medical Director of the Transplant Unit at the Italian Hospital in Buenos Aires. He is a consultant in Gastroenterology and Hepatology and has over 25 years in the management of patients affected with hepato-biliary diseases and liver transplantation. Gadano is chief of the Research Department at the same Institution. Since the early 1990’s, he conducted, coordinated and participated in several international and national clinical trials in the fields of viral hepatitis, complications of cirrhosis, hepatocellular carcinoma and liver transplantation.

    Gadano is a member of several intra-hospital and national committees, including the Argentinian Association for the Study of Liver Diseases (AAEEH), Argentinian Society of Gastroenterology (SAGE), the Argentinian Society of Transplantation (SAT). He is also a member of the Latin American Society of Liver Diseases (ALEH), the European Association of the Study of Liver Disease (EASL) and member of the board of Journal of Hepatology. He is part of the Board of the International Club of Ascitis (ICA). He was the president of the Argentinian Society of Transplantation (SAT), Argentinian Association for the Study of Liver Diseases (AAEEH) and the ICALMA Foundation. He has published over 150 original papers in official and peer-reviewed journals, and many other journal articles, book chapters and textbooks. He presented, during the last twenty years, hundreds of original papers at conferences and has chaired numerous sessions and symposia at national and international congresses.

    Jidong Jia

    Jidong Jia, MD, PhD, is a Hepatologist and Director of the Liver Research Centre at the Beijing Friendship Hospital, Capital University in Beijing, China. He is also immediate past President of the Chinese Society of Hepatology, Past President of APASL (2009-2010), Vice President of IASL. Dr. Jia also serves as associate editor for Journal of Gastroenterology & Hepatology, Hepatology International and Liver International. His clinical interests include the chronic viral hepatitis and autoimmune liver diseases. His research work mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis.

    Mindie H. Nguyen (Moderator)

    Mindie Nguyen, MD is a professor of medicine and director for the Hepatology Fellowship and Clerkship in the Division of Gastroenterology and Hepatology and Liver Transplant at Stanford University Medical Center. She is an active clinician with a large general and transplant liver practice, and an active researcher in viral hepatitis, non-alcoholic fatty liver disease and liver cancer with over 250 publications including first or senior authorship in leading journals such as The New England Journal of Medicine, Lancet Gastroenterology and Hepatology, Gastroenterology, Journal of Hepatology and HEPATOLOGY.

    Nguyen has served as editorial/advisory board member for major journals such as Lancet Gastroenterology and Hepatology, Gastroenterology and HEPATOLOGY. She is currently Chair of the Hepatitis B Special Interest Group for the American Association for the Study of Liver Diseases (AASLD) and an Officer/Treasurer and Executive Governing Council for the International Association for the Study of Liver Diseases (IASL). She is the lead Principal Investigator for several multinational studies involving over 40 centers in the U.S. and Asia Pacific. She serves as Board of Directors or Advisors for non-profit organizations locally and nationally in the U.S; and in collaboration with the local country Ministries of Health and Sports, she has directed scientific programs of continuing medical conferences for physicians in Mongolia and Myanmar. As an active teacher and educator, she has mentored over 130 trainees from high school students to undergraduate, medical, Masters’ and PhD students in Public Health/Epidemiology, clinical residents/fellows, postdoctoral research fellows, and faculty at Assistant/Associate Professor rank from Stanford University as well as other institutions in the U.S. and overseas.

    Harry Janssen (Moderator)

    Harry Janssen, MD, PhD, FAASLD is a professor of medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in hepatology. He currently works at Toronto General Hospital as chief of hepatology and director of the Toronto Centre for Liver Disease.

    Dr. Janssen graduated from medical school in the Netherlands. During his study he spent one year as research student in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in hepatitis B. Following his training in Internal Medicine and Gastroenterology in the Netherlands, he returned to the Mayo Clinic for a Research Fellowship in Hepatology. In 2001, he became a faculty member and in 2006 he was appointed as full professor of medicine and chief of the Section Liver Diseases and Transplantation in Rotterdam. In 2013, he came to Canada where he merged three liver programs into the Toronto Centre for Liver Disease, based at the Toronto General Hospital, University Health Network.

    Dr. Janssen has coordinated numerous clinical and translational studies on treatment for chronic viral hepatitis and other liver diseases. His main research interest is cure of chronic hepatitis B. He has published more than 500 original peer-reviewed papers and many book chapters. His H-index is over 100 and he has been cited 45,000 times (Google Scholar). He has received several prestigious international awards and has mentored over 50 PhD students, of whom many have taken leadership positions in the field of hepatology or virology.

  • 2020 Webinar: Global Public Health Strategies for the Prevention of ALD in 2020

    Contains 2 Component(s) Recorded On: 09/01/2020

    Webinar hosted by the Alcohol-associated Liver Disease Special Interest Group on September 1, 2020.

    Alcohol-associated liver disease (ALD) is the leading cause of cirrhosis worldwide. Harmful drinking, especially among youth and women, is increasing.  A global alliance and discussion about effective public health strategies is needed. This webinar with a global outreach focus on ALD will involve the participation of the four major liver societies worldwide. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Alexandre Louvet

    Alexandre Louvet, MD is professor of hepatology in the gastroenterology department of the University Hospital of Lille, France, headed by Prof. Philippe Mathurin. He earned his medical degree from the University of Lille. He received his PhD degree after a fellowship in the Institut Mondor de Recherche Biomédicale in Créteil, France, where he worked on the role of the endocannabinoid system in alcoholic liver disease in mice. His clinical interests include alcoholic liver disease, non-alcoholic fatty liver disease, hepatocellular carcinoma and viral hepatitis.

    He is involved in both clinical and basic research. His main topic in research is alcoholic hepatitis (natural history, treatment, disease modeling, transplantation, and pathophysiology). He has published several papers on the management of patients with severe alcoholic hepatitis. He is a member of the governing board of the French Association for the Study of the Liver (AFEF), of the editorial board of the Journal of Hepatology and a reviewer for several journals specialized in hepatology.

    Cyriac Philips

    Cyriac Philips, MD, MBBS, DM is the Clinical Lead, The Liver Unit, Cochin Gastroenterology Group, based in Kochi, and Director of Monarch Liver Lab, Department of Clinical and Experimental Gastroenterology and Hepatology at the Ernakulam Medical Center Hospital, Kochi, Kerala, India. He is a two-time Clinical Hepatology plenary awardee (2015, 2017) of the American Association for Study of Liver Diseases (AASLD) and four-time AASLD and European Association for Study of Liver (EASL) Young Investigator Award winner (2015, 2016, 2017, 2017) and recipient of the prestigious President of India Excellence in Hepatology from Institute of Liver and Biliary Sciences, New Delhi in 2016. He has published over 140 peer-reviewed studies in high impact journals including Gastroenterology; HEPATOLOGY; Journal of Hepatology; Clinical Gastroenterology and Hepatology and the American Journal of Gastroenterology. His interests and expertise include study of the gut microbiome and its modulation in severe alcoholic hepatitis and sepsis, portosystemic shunt syndrome, drug induced liver injury especially Ayurvedic herbals and infections in cirrhosis. His pioneering work in the field of liver diseases has been the introduction of healthy donor fecal transplant for severe alcoholic hepatitis and novel data on clinical outcomes, toxicology and chemical analysis of Ayurvedic herbal induced liver injury for which he received the Indian National Award for Best Paper in 2019 from The Indian Society of Gastroenterology and SpringerNature.

    Juan Pablo Arab (Moderator)

    Juan Pablo Arab, MD is Assistant Professor of Medicine at the Pontificia Universidad Catolica de Chile School of Medicine. Trained at the P. Univ Catolica, Chile and Mayo Clinic, Rochester, MN, Dr. Arab is a Gastroenterology and Hepatology specialist, Transplant Hepatologist and Physician Scientist with interest in translational and clinical research in alcohol-associated liver disease and non-alcoholic fatty liver disease. He has published more than 90 peer-reviewed papers on gastrointestinal and liver diseases in high-impact factor journals, co-authored several book chapters and delivered lectures on liver-related topics at national and international meetings. He has also participated in the generation of clinical practice guidelines for alcohol-related liver disease, nonalcoholic fatty liver disease, and hepatorenal syndrome in Latin America and regularly serves as expert reviewer of research grants and scientific research abstracts for multiple societies, funding agencies and international peer reviewed journals. Additionally, he is spearheading an international collaboration group that aims to study alcohol-related liver disease and non-alcoholic fatty liver disease. Dr. Arab is a member of the American Association for the study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Latin-American Association for the Study of the Liver (ALEH). He is currently the Secretary of the Special Interest Group on alcohol-related liver disease of the AASLD and Vice-Chairs its global outreach subcommittee. Additionally, he is the Vice-President of the Chilean Hepatology Association.

    John P. Rice (Moderator)

    John P. Rice, MD is an Assistant Professor of Medicine and the Section Chief of Hepatology in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine and Public Health. Dr. Rice completed his medical degree at the University of Nebraska College of Medicine. He completed his Internal Medicine training and served as Chief Resident at McGaw Medical Center of Northwestern University in Chicago, IL. He completed Gastroenterology and Hepatology and Transplant Hepatology fellowships at the University of Wisconsin Hospital and Clinics. He currently serves as a staff transplant hepatologist.

    Dr. Rice’s clinical and clinical research interests include management of alcohol-associated liver disease (ALD), alcohol use disorder, and liver transplant selection and liver transplant outcomes in ALD. Dr. Rice serves as the Chair of the Global Outreach subcommittee in the AASLD ALD special interest group.

  • 2020 Webinar: Dietary Recommendations for NAFLD Patients: What Do I Tell My Patients?

    Contains 2 Component(s) Recorded On: 08/19/2020

    Webinar hosted by the Non-alcoholic Fatty Liver Disease Special Interest Group on August 19, 2020.

    The purpose of this webinar is to provide the audience with the most current data regarding dietary intervention in NAFLD. The first talk "How Much Weight Should I Lose?" will focus on: he amount required for weight loss; changes in histology; and likelihood of success and exercise data. The second talk "Which Diet Should I Follow and Which Food I Should Eat or Avoid?" will include: types of diet; data on international diets; alcohol use; coffee; red meat; fructose; and others. The third talk "How Should I Start My Diet and How Would I Follow Up?" will include practical examples from NAFLD clinics. A patient with NAFLD with join the presenter during the third talk. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Manuel Romero Gómez

    Manuel Romero Gómez (Sevilla, Spain, 1967) is Full-Professor of Medicine at the University of Seville, Spain. Digestive Diseases Department at Virgen del Rocío University Hospitals. Head of group for translational research in liver diseases (SeLiver) at Institute of Biomedicine of Seville (IBIS). Coordinator of the Spanish Registry of NAFLD/NASH (HepaMET) and co-coordinator of the EASL supported European Registry of NAFLD. Principal Investigator in the Spanish Network for Research in Digestive and liver diseases (CiberEHD). He is participating actively in NASH-related European Projects: Sub-project-7 leader at European project FLIP (2010-2013), National Leader (SPAIN) at LITMUS (2017-2022) and coordinator of NASH-PI (2020-2021) an international grant.

    Member of commission 527 from ISCIII and Spanish Agency for Evaluation of Research (AEI). He received the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014. He was awarded with the Medal of The City of Seville in 2016. He has published more than 300 peer-reviewed papers on gastrointestinal and liver diseases with H-index 59. He has protected 10 patents and participated as PI in more than 20 competitive grants for research.

    Michelle Long

    Michelle Long, MD, MSc is a clinical investigator and hepatologist at the Boston University School of Medicine and Boston Medical Center. Dr. Long is the Director of the Boston Medical Center’s Nonalcoholic Fatty Liver Disease (NAFLD) Research Center and she is the Director of Clinical Research for the Section of Gastroenterology & Hepatology in the Department of Medicine. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD, including the overlap between NAFLD and cardiometabolic disease. Dr. Long is an investigator in the Framingham Heart Study where she is the Principal Investigator on a multi-year, multi-generational effort to evaluate the genetic and clinical correlates of liver fat and fibrosis as measured by transient elastography. She is the Principal Investigator for several ongoing Phase II and Phase III clinical trials in NAFLD. Dr. Long has received research funding from the National Institute of Health, Echosens Corporation, Gilead Sciences, The Doris Duke Research Foundation, and Boston University. She serves on the Liver-Biliary Council for the American Gastroenterological Association and on the Training and Workforce Committee for the American Association for the Study of Liver Diseases. Dr. Long is also an Associate Editor for Liver International.

    Zachary Henry

    Zachary Henry, MD is a transplant hepatologist at the University of Virginia in Charlottesville, Virginia. He works in our general hepatology and liver transplant clinics. In 2015, Dr. Henry started a specific clinic for patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis that is focused on lifestyle interventions for weight management. This clinic is a multi-disciplinary clinic run in conjunction with UVA endocrinology and cardiology specialists to approach related issues of metabolic syndrome in these patients. To that end , he underwent training in Obesity Medicine in 2017 and became certified by the American Board of Obesity Medicine in 2018. His research interests focus on lifestyle modfications for non-alcoholic fatty liver disease and the potential impact different groups of medications may have on these interventions.

    Wayne Eskridge

    Wayne Eskridge worked as an electrical engineer in software and electronics through a 50-year professional career. Eskridge held executive positions in both public and private corporations with worldwide responsibilities, and from startups to Fortune 500 firms. He was first diagnosed with liver disease in 2010, which progressed to cirrhosis by 2015. He has successfully managed his disease and as a result he became aware of an acute need for an educational resource from a patient perspective. His desire to help others avoid his experiences led him to the decision to become a patient advocate and to create the Fatty Liver Foundation.

    Mazen Noureddin (Moderator)

    Mazen Noureddin, MD, MHSc, is the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He is a faculty at the Division of Digestive and Liver Diseases which was ranked #2 in gastroenterology and gastrointestinal surgery in the 2019 US News and World Report.

    His focus is on clinical and translational research in the area of NAFLD. Dr. Noureddin has conducted more than 30 investigational clinical studies of novel treatments for NASH. In addition, he has an interest in non-invasive testing and biomarkers of the field, especially metabolomics, serum biomarkers, trainset elastography, and magnetic resonance imaging techniques. Dr. Noureddin has published in all these areas. He is a member of the Liver Forum (FDA-AASLD-Academic Colloquium), standardizing pathways to translate therapeutic agents to clinical practice. He has given many invited lectures on NAFLD/NASH at national (e.g. American Gastroenterological Association, AASLD) and international society meetings and serves on several steering committees / advisory boards for industry.

  • Fundamentals of Liver Disease - Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis 2.0

    Contains 31 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    DESCRIPTION
    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
    Pathogenesis of Non-alcoholic Steatohepatitis
    Non-Invasive Determination of Advanced Disease in NAFLD
    Lifestyle Interventions: Setting Goals and Recommendations
    Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
    Bariatric Surgery: Is the Cure for NASH in the OR?
    Managing NASH Cirrhosis and Assessment for Liver Transplant
    Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
    Emerging Treatments for Non-Alcoholic Steatohepatitis

    Release date: June 15, 2020
    Expiration date: June 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Continuing Education (CE): For a maximum of 4.50 Contact Hour
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    -9 online, narrated modules 15 to 20 minutes in length
    -Pre- and post-test questions for each module
    -Evaluation for CME or CE credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim either CME or CE. MOC is available for learners who complete and earn CME.

    COPYRIGHT 
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION
    For questions on CME and  MOC content or LiverLearning®, contact online_education@aasld.org
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objective:
    • Identify patients with liver disease, specifically NASH/NAFLD
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for NASH/NAFLD
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) 
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  
    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS
    Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by June 14, 2023

    CLAIMING ABIM MOC POINTS 
    Physicians seeking ABIM MOC credit must complete the enduring material by June 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2023 for individuals who successfully complete MOC.

    CLAIMING CE CREDITS
    Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by June 14, 2023

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-test

                 o    Watch video presentation

                 o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Mary E. Rinella, MD, FAASLD
    Faculty
    Consulting: AbbVie, NuSirt, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, Genfit, Enanta, BMS, Immuron, CymaBay, Merck, Viking, Madrigal, Genesis, Metacrine, Allergan, Thetis, Fractyl, 3vBio, Coherus, Terns, Boehringer Ingelheim and Takeda
    Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)

    Arun J. Sanyal, MD, MBBS
    Faculty
    Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
    Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
    Stock Options: Genfit
    President of Sanyal Bio

    Leon A. Adams, MBBS, FRACP, PhD
    Faculty
    Patents regarding Hepascore
    Employer has a licensing agreement with Quest Diagnostics regarding its commercialization

    Brent Neuschwander-Tetri, MD
    Faculty
    Consulting: Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Cymabay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead, High Tide, Histolndex, Intercept, Lipocine, Llama, Madrigal, Medimmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus and Siemens
    Grants/research support: Allergan, BMS, Cirius, Cymabay, Enanta, Galectin, Genfit, Gilead, Intercept, Madrigal, NGM and Prometheus

    Kathleen E. Corey, MD, MPH, MMSc
    Faculty
    Nothing to disclose

    Philippe Mathurin, MD, PhD
    Faculty
    Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag and Bayer Healthcare pharmaceutical companies

    Kymberly D. Watt, MD

    Faculty
    Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals and Gilead

    Dawn M. Torres, MD
    Faculty
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD
    Faculty
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Sanjeeva Arora, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author

    Guadalupe Garcia-Tsao, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Advisory Board: Intercept, Conatus
    Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
    Research Grants: Intercept

    Leslie Hayes, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Minhhuyen Nguyen, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Vicki Shah, PA
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

    Raj Vuppalanchi, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, MSN
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • 2020 Webinar: Hepatitis C: Infection Beyond the Liver

    Contains 2 Component(s) Recorded On: 05/19/2020

    Webinar hosted by the Hepatitis C Special Interest Group on May 19, 2020.

    Extrahepatic manifestations of HCV contribute to its increased overall mortality rate in those infected relative to those who aren’t; associated cardiovascular, neoplastic and renal manifestations can contribute significantly to a patient’s truncated lifespan beyond liver-related morbidity. This webinar will address the recognition and the treatment of extrahepatic manifestations of chronic HCV infection. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Miklos Z. Molnar

    Dr. Miklos Z. Molnar is an Hungarian-American Transplant Nephrologist and an Associate Professor of Medicine at University of Tennessee Health Science Center, Memphis, TN. He is also affiliated with James D. Eason Transplant Institute in Methodist University Hospital, also in Memphis. Dr. Molnar serves as Director of AST Transplant Nephrology Program at James D. Eason Transplant Institute in Methodist University Hospital.

    Dr. Molnar obtained his MD and PhD from Semmelweis University, Budapest, Hungary. He received additional medical training in Hungary and board certified in internal medicine, nephrology and transplant medicine in Europe. Dr Molnar immigrated to US in 2010, spent two years as post-doc fellow at Harbor UCLA, and obtained his US residency and transplant nephrology fellowship at University of Tennessee Health Science Center, Memphis, Tennessee and nephrology fellowship at University of Toronto, Toronto, Canada. Dr. Molnar is board certified in internal medicine and nephrology.

    Dr. Molnar is an author of more than 240 articles in a field of nephrology and transplant medicine. He serves as editorial board member in several journals, and current Associate Editor in Transplant International. He also served as PI in a recent R21 grant.

    Francesco Negro

    Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from 1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989.

    After having spent some time back in Torino, he joined the University Hospitals of Geneva, Switzerland, in 1994. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis.

    He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring more than 300 peer-reviewed manuscripts in the field of hepatology. After serving as Educational Councilor within the Governing Board of the European Association for the Study of the Liver (EASL), he is currently Treasurer of EASL for the period 2019-2024. He is also chairing the Swiss Hepatitis C Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

    Harrys A. Torres

    Harrys A. Torres, MD, FACP, FIDSA, is an Associate Professor of Medicine in the Department of Infectious Diseases, Infection Control and Employee Health and an Adjunct Associate Professor, Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine, and infectious disease, with additional accreditations on HIV/AIDS and Tropical Medicine and Hygiene. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the US, and likely in the world, devoted to managing HCV in cancer patients.

    Dr. Torres is a member of numerous national committees for professional societies such as the Infectious Diseases Society of America, American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver and the American Society for Blood and Marrow Transplantation. He is the secretary of the AASLD Special Interest Group on HCV and the principal investigator for multiple research grants. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation. His work addressed the fact that HCV is a neglected condition in cancer patients. Additionally, he has discovered new associations between HCV and other cancers (e.g. Head and Neck cancers). He has also documented the effectiveness, benefits, and safety of antiviral therapy in HCV-patients with cancer including those with hepatocellular carcinoma and B-cell non-Hodgkin lymphoma.

    Dr. Torres is co-author of more than 100 articles published in peer-reviewed journals, including CA: A Cancer Journal for Clinicians, Gastroenterology, HEPATOLOGY, Journal of Hepatology, Journal of the National Cancer Institute, Lancet Haematology, American Journal of Gastroenterology, Leukemia, Clinical Infectious Diseases, Blood, Nature Reviews Clinical Oncology, Cancer, Liver International, and Journal of Viral Hepatitis with many of his publications accompanied by editorials. He has presented almost 130 abstracts in international meetings and written 8 book chapters. His work on HCV has been awarded multiple times by the AASLD and American Society of Clinical Oncology among others. Dr. Torres lectures widely nationally and internationally on HCV in cancer patients and trains infectious diseases and gastroenterology fellows in the diagnosis and management of HCV in this special patient population. By providing evidence and innovative approaches, his body of work has changed the standard of care for HCV-infected cancer patients.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Chronic Hepatitis C 101: The Basics

    Contains 2 Component(s) Recorded On: 04/28/2020

    Webinar hosted by the Hepatitis C Special Interest Group on April 28, 2020.

    As chronic hepatitis C infection therapy moves outside the realm of specialty care, more providers want to be well-versed in both identifying patients and treating them appropriately. This webinar is designed for the HCV-treating novice. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lisa Catalli

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.

    Natarajan Ravendhran

    Dr. Ravendhran is a hepatologist in Baltimore, Maryland. He is trained in hepatology by Dr. Schiff at University of Miami. He is board-certified in gastroenterology and transplant hepatology. He is a medical director for the research department in Digestive Disease Associates in Baltimore. He holds faculty position at Johns Hopkins University as a clinical assistant professor in the department of medicine. He is a Fellow of American Association for Study of Liver Diseases.

    He is actively involved in clinical trials, teaching and having a busy clinical practice. He has conducted more than 100 clinical trials in hepatology regarding chronic hepatitis C treatment, hepatitis B treatment and currently involved in many clinical trials with non-alcoholic fatty liver disease. He has published in Journal of Hepatology, Journal of American College of Gastroenterology, and New England Journal of Medicine.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Prevention and Management of Ascites in Cirrhosis: Controversies and New Approaches

    Contains 2 Component(s) Recorded On: 03/10/2020

    Webinar hosted by the Portal Hypertension Special Interest Group on March 10, 2020.

    This webinar will review recent important advances in understanding of how to care for patients with cirrhosis and ascites. Specifically, it will discuss how to risk stratify patients for ascites and new strategies for ascites prevention. In addition, it will address evidence-based approaches to the management of ascites among patients who have chronic kidney disease, a challenging and common clinical scenario. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Scott W. Biggins (Moderator)

    Dr. Scott W. Biggins is Chief of Hepatology, Director of the Liver Care Line for UW Medicine, and Director of the Center for Liver Investigation Fostering Discovery (C-LIFE) at the University of Washington. Dr. Biggins is a national recognized clinician and researcher in the field of Hepatology. He received his undergraduate degree in chemical engineering (bioengineering option) from the University of California, Los Angeles (1994) and his medical degree from the University of Southern California (1999). He completed a residency in Internal Medicine at Oregon Health & Science University (2002) and his Gastroenterology fellowship training at the University of California, San Francisco (2005). He was also awarded a Master’s degree in Clinical Research from the University of California, San Francisco (2006).

    Dr. Biggins' clinical interests are the risk reduction and management of complications of end-stage liver disease, and the clinical evaluation and care of liver transplant candidates and recipients. He has been recognized as a fellow of American Association for the Study of Liver Diseases (FAASLD), American Society of Transplantation (FAST), and American Gastroenterological Association (AGAF). He is Vice Chair of the AASLD Special Interest Group (SIG) for Portal Hypertension.

    His research is focused on complications of portal hypertension, improving recipient and donor selection for liver transplantation and revising organ allocation algorithms in order to maximize patient outcomes. He has received research funding from the American Liver Foundation, National Institutes of Health and the Agency for Healthcare Research and Quality. He has published more than 75 papers in peer-reviewed journals including the New England Journal of MedicineGastroenterology, HEPATOLOGY, and Liver Transplantation.

    Elizabeth Verna (Moderator)

    Dr. Elizabeth Verna is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist.

    In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.

    Juan G. Abraldes

    Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004). He was a faculty member of the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to the University of Alberta.

    He has published more than 200 papers on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis and was the chair of the AASLD Special Interest Group in Portal Hypertension between 2017 and 2018.

    Florence Wong

    Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.

    She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.

    She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.